Terumo Europe

Terumo logo

TERUMO® is a Japanese company, which is appreciated worldwide for its innovations and the outstanding qualities of its systems.

The intercultural experience focuses attention on the company's strategy: to continue developing the link between European requirements, expertise in new technologies, new therapies and Japanese engineering know-how.

Leader in minimally invasive treatment and devices, TERUMO® is dedicated to help Patients suffering from Vascular and Coronary diseases, offering a wide range of quality products for Interventional Radiology (Embolotherapy, Periphearl, Angiography), Interventional Cardiology, Transfusion, Cardiovascular systems, Clinical Tests systems and patient Monitoring, comply with the highest standards in the medical world.

Pioneering the development of hydrophilic concepts, TERUMO® EUROPE INTERVENTIONAL SYSTEMS is today focused on the expansion of therapeutic devices dedicated to Interventional procedures.

Headquarters

TERUMO EUROPE
INTERVENTIONAL SYSTEMS
Parc Ariane - Bât. Jupiter
1 rue Hélène Boucher
78284 Guyancourt Cedex
FRANCE
Tel 33 1 39 30 95 75
Fax 33 1 39 30 95 70
Email: angioandinterventional.systems@terumo-europe.com

Germany

TERUMO DEUTSCHLAND GmbH
Hauptstrasse 87
D-65760 Eschbor n
GERMANY
Tel 49 6196 8023 0
Fax 49 6196 8023 200
Email : terumo.germany@terumo-europe.com

France

LABORATOIRES TERUMO FRANCE S.A.
Parc Ariane - Bât. Uranus
1 rue Hélène Boucher
78284 Guyancourt Cedex
FRANCE
Tel 33 1 30 96 13 00
Fax 33 1 30 43 60 85
Email : terumo.france@terumo-europe.com

Italy, Greece and Turkey

TERUMO ITALIA SRL
Via Simone Martini, 143-145
00142 Roma RM
ITALY
Tel 39 06 51 96 14 20
Fax 39 06 50 30 407
Email : terumo.italy@terumo-europe.com

Spain and Portugal

TERUMO EUROPE ESPAÑA SL
Edificio Torre La Garena
Av da. Juan Carlos 1o Planta 7a
28806 Alcalá de Henares
Madrid Spain
Tel 34 902 10 12 98
Fax 34 902 10 13 58
Email : terumo.spain@terumo-europe.com

United Kingdom and Ireland

TERUMO UK Ltd
Tamesis
The Causeway
Egham
Surrey TW20 9AW
United Kingdom
Tel 44 178 447 6200
Fax 44 178 447 6201
Email : terumo.uk@terumo-europe.com

Belgium, Luxemburg and The Netherlands

TERUMO EUROPE NV
BENELUX SALES DIVISION
Researchpark Zone 2 - Haasrode
Interleuvenlaan 40
B-3001 Leuven
BELGIUM
Tel 32 16 39 25 80 (Belgium)
Fax 32 16 39 25 99 (Belgium)
Tel 0800 0220 396 (Netherlands)
Fax 0800 0220 414 (Netherlands)
Email : terumo.benelux@terumo-europe.com

Estonia, Latvia, Lithuania, Poland, Czech Republic, Slovakia, Hungary, Romania, Slovenia, Croatia, Bosnia and Herzegovina, Bulgaria and Yugoslavia

EMERGING MARKET DIVISION (EXPORT)
OFFICE OF TERUMO EUROPE NV
Researchpark Zone 2 - Haasrode
Interleuvenlaan 40
B-3001 Leuven
BELGIUM
Tel 32 16 38 13 26
Fax 32 16 40 02 49
Email : terumo.export@terumo-europe.com

Russia

MOSCOW REPRESENTATIVE
OFFICE OF TERUMO EUROPE NV
4, Ivana Franko St,
Moscow, Russia, 121108
Tel 7 495 234-3303
Fax 7 495 234-3303
Email : terumo.export@terumo-europe.com

Sweden

TERUMO SWEDEN AB
Nya Varvet
Byggnad 90
SE-426 71 Västra Frölunda
Sweden
Tel 46 31 748 58 80
Fax 46 31 748 58 90
Email : terumo.nordic@terumo-europe.com

Denmark

TERUMO DENMARK
Filial of Terumo Sweden AB
Tel 46 31 748 58 80
Fax 46 31 748 58 90
Email : terumo.nordic@terumo-europe.com

Terumo Medical do Brasil Ltda

Rua Gomes de Carvalho
1507 - cj. 15, e 152 Vila Olimpia
CEP: 04547-005
Sao Paulo
SP - Brasil

Tel: 55-11-3594-3800
Fax: 55-11-3594-3829

Terumo Chile Ltda.

Carmencita 25
Oficina 22 piso 2
Edificio Central Park
Las Condes
Santiago Chile
(ZIP code 755-0157)

Tel: 56-2-480-9600
Fax: 56-2-480-9608

Terumo Colombia Andina S.A.S.

Calle 72
No.9-55
Oficina 401
Bogota
Colombia

Tel: 57-1-217-7772

Terumo Medical de Mexico S.A. de C.V.

Av. Prolongacion Paseo de la Reforma
No. 1236
Piso 6
Colonia Santa Fe
C.P. 05348
Delegacion Cuajimalpa
Mexico D.F.
Mexico

Tel: 52-55-1085-0770
Fax: 52-55-1085-0771

Terumo Latin America Corporation

Doral Corporate Center I
6th Floor
8750 NW 36th Street
Miami
FL 33178 U.S.A

Tel: 1-305-477-4822
Fax: 1-305-477-4872

Regulatory notices and product safety data

Worldwide (excluding USA)

Bead Block™ is CE marked and indicated for the treatment of a variety of hypervascular tumours (including Uterine Fibroids) and arteriovenous malformations (AVMs). For full prescribing information please refer to Bead Block instructions for use.

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). Both indications may not be available in your territory. For full prescribing information please refer to DC Bead instructions for use.

DC BeadM1™ is indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead M1 instructions for use.

USA

In the USA, Bead Block™ is indicated for the treatment of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to Bead Block USA Instructions for use.

LC Bead™ is cleared by the FDA for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to LC Bead instructions for use.

LC Bead M1™ is cleared by the FDA for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). For full prescribing information please refer to LC Bead M1 instructions for use.

DC Bead is not currently available for sale or distribution in the USA. Both indications may not be available in your territory. 

DC Bead M1 is not currently available for sale or distributions in the USA. 

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

DC BeadM1 is primarily intended as an embolic agent to treat vessels supplying malignant colorectal cancer metastasised to the liver (mCRC). DC BeadM1 is also compatible with irinotecan, which can be loaded prior to embolisation and then, as a secondary action, elute a local, controlled and sustained dose to the mCRC after embolisation. For full prescribing information please refer to DC BeadM1 Canada Instructions for Use  

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.

Hong Kong

PRECISION Bead™ is indicated for the delivery of Doxorubicin, a chemotherapeutic agent for the treatment of malignant hypervascular tumours, where Trans Arterial Embolisation (TAE) is not contraindicated.